Concourse Financial Group Securities, Inc. Moleculin Biotech, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.52 Billion
Q1 2024

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$0.41 - $0.86 $0 - $0	0 New	0 $0
Q3 2023 Oct 30, 2023	BUY	$0.38 - $0.72 $0 - $0	0 New	0 $0
Q3 2023 Oct 25, 2023	BUY	$0.38 - $0.72 $0 - $0	0 New	0 $0
Q2 2023 Aug 10, 2023	BUY	$0.54 - $0.95 $0 - $0	0 New	0 $0
Q1 2023 May 15, 2023	BUY	$0.9 - $1.34 $0 - $0	0 New	0 $0

Q4 2022 Jan 30, 2023	BUY	$0.85 - $1.49 $0 - $0	0 New	0 $0
Q3 2022 Nov 15, 2022	BUY	$1.15 - $1.9 $0 - $0	0 New	0 $0
Q2 2022 Aug 09, 2022	BUY	$1.19 - $2.0 $0 - $0	0 New	0 $0
Q1 2022 May 09, 2022	BUY	$1.23 - $1.9 $0 - $0	0 New	0 $0
Q4 2021 Feb 07, 2022	BUY	$1.64 - $2.83 $0 - $0	0 New	0 $0
Q3 2021 Nov 09, 2021	BUY	$2.7 - $3.59 $0 - $0	0 New	0 $0
Q2 2021 Aug 13, 2021	BUY	$3.21 - $4.06 $0 - $0	0 New	0 $0
Q1 2021 May 13, 2021	BUY	$3.7 - $6.42 $0 - $0	0 New	0 $0

Others Institutions Holding MBRX

# of Institutions

Shares Held

3.35K

Call Options Held

Put Options Held

View Full List

About Moleculin Biotech, Inc.

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $124M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

More about MBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account